Arkolith/Insider Trading/XLO/Form 4

Gilead Sciences, Inc.

10% OwnerXilio Therapeutics, Inc. (XLO) · full profile →Form 4 · filed Dec 19, 2024
Net Buying
Open-Market Buys
$1.8M
Open-Market Sells
$0
Net Open-Market Flow
$1.8M
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 18, 2024Buy(P)1.8M$1.04$1.8M9.1M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 18, 2024Buy(P)6.1M$1.04$6.3M10.0M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001062993-24-020910) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Xilio Therapeutics, Inc.

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.

Form 4 insider API

Open-market buys and sells, cluster scans, company flows.

insider.transactions

13F holdings API

Owners, holdings, deltas, point-in-time portfolios.

stock.owners

MCP quickstart

Connect an agent, mint a key, make the first call.

/api/mcp